Novel nitric oxide donor (FK409) ameliorates liver damage during extended liver resection with warm ischemia in dogs

被引:28
作者
Aiba, M
Takeyoshi, I
Ohwada, S
Kawashima, Y
Iwanami, K
Sunose, Y
Yamada, T
Tsutsumi, H
Matsumoto, K
Morishita, Y
机构
[1] Gunma Univ, Sch Med, Dept Surg 2, Maebashi, Gumma 3718511, Japan
[2] Nippon Med Coll, Dept Pathol, Kawasaki, Kanagawa, Japan
关键词
D O I
10.1016/S1072-7515(01)01002-X
中图分类号
R61 [外科手术学];
学科分类号
摘要
BACKGROUND: Nitric oxide attenuates ischemia-reperfusion injury by maintaining organ circulation through its actions as a vasoregulator, an inhibitor of platelet aggregation, and an attenuator of leukocyte adhesion. Otherwise, the harmful effects of enhanced nitric oxide production induced by inducible nitric oxide synthase mediate ischemia-reperfusion injury. FK409 has been characterized as a spontaneous nitric oxide donor. The aim of this study was to evaluate the effects of FK409 on extended liver resection with ischemia using a canine model. STUDY DESIGN: Adult mongrel dogs were subjected to 60 minutes of warm ischemia by partial inflow occlusion. After reperfusion the nonischemic lobes were resected and the remnant liver function was evaluated. The dogs were divided into two groups: the control group (n = 7) and the FK409 group (n = 6), which was given FK409 through the portal vein. RESULTS: The hepatic tissue blood flow, serum liver enzymes levels, and serum endothelin-1 level after reperfusion were significantly better in the FK409 group than in the control group. Electron microscopy demonstrated that endothelial cells and Ito cells were well-preserved in the FK409 group. The 3-day survival rate was statistically better in the FK409 group (67%) than in the control group (14%). CONCLUSIONS: FK409 appears to have protective effects during extended liver resection with ischemia. (J Am Coll Surg 2001;193:264-271. (C) 2001 by the American College of Surgeons).
引用
收藏
页码:264 / 271
页数:8
相关论文
共 37 条
  • [1] ENDOTHELIN-1-LIKE IMMUNOREACTIVITY IN HUMAN URINE
    ANDO, K
    HIRATA, Y
    TAKEI, Y
    KAWAKAMI, M
    MARUMO, F
    [J]. NEPHRON, 1991, 57 (01): : 36 - 39
  • [2] PRESENCE OF IMMUNOREACTIVE ENDOTHELIN IN HUMAN-PLASMA
    ANDO, K
    HIRATA, Y
    SHICHIRI, M
    EMORI, T
    MARUMO, F
    [J]. FEBS LETTERS, 1989, 245 (1-2) : 164 - 166
  • [3] BLANER WS, 1985, J LIPID RES, V26, P1241
  • [4] DECOMPOSITION OF FK-409, A NEW VASODILATOR - IDENTIFICATION OF NITRIC-OXIDE AS A METABOLITE
    DECOUT, JL
    ROY, B
    FONTECAVE, M
    MULLER, JC
    WILLIAMS, PH
    LOYAUX, D
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 1995, 5 (09) : 973 - 978
  • [5] GRIFFITH BP, 1985, SURG GYNECOL OBSTET, V160, P270
  • [6] Endothelin-1 induces vasoconstriction and nitric oxide release via endothelin ETB receptors in isolated perfused rat liver
    Higuchi, H
    Satoh, T
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1997, 328 (2-3) : 175 - 182
  • [7] FK409, A NOVEL VASODILATOR ISOLATED FROM THE ACID-TREATED FERMENTATION BROTH OF STREPTOMYCES-GRISEOSPOREUS .1. TAXONOMY, FERMENTATION, ISOLATION, AND PHYSICOCHEMICAL AND BIOLOGICAL CHARACTERISTICS
    HINO, M
    IWAMI, M
    OKAMOTO, M
    YOSHIDA, K
    HARUTA, H
    OKUHARA, M
    HOSODA, J
    KOHSAKA, M
    AOKI, H
    IMANAKA, H
    [J]. JOURNAL OF ANTIBIOTICS, 1989, 42 (11) : 1578 - 1583
  • [8] COMPARISON OF ANTIPLATELET EFFECTS OF FK409, A SPONTANEOUS NITRIC-OXIDE RELEASER, WITH THOSE OF TRK-100, A PROSTACYCLIN ANALOG
    HIRASAWA, Y
    NISHIO, M
    MAEDA, K
    YOSHIDA, K
    KITA, Y
    [J]. EUROPEAN JOURNAL OF PHARMACOLOGY, 1995, 272 (01) : 39 - 43
  • [9] EFFECT OF FK409, A NOVEL NITRIC-OXIDE DONOR, ON ACUTE EXPERIMENTAL MYOCARDIAL-ISCHEMIA
    ISONO, T
    SATO, N
    KOIBUCHI, Y
    SAKAI, S
    YAMAMOTO, T
    OZAKI, R
    MORI, J
    KOHSAKA, M
    OHTSUKA, M
    [J]. JAPANESE JOURNAL OF PHARMACOLOGY, 1993, 62 (03) : 315 - 324
  • [10] Kamoshita N, 1997, J HEART LUNG TRANSPL, V16, P1062